Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
UniQure said its gene therapy AMT-130 missed statistical significance on the main goal of slowing Huntington’s disease progression in a four-year analysis, with 44% slowing at 48 months in 12 high-dose patients versus an external control.
UniQure NASDAQ:QURE said its gene therapy for Huntington's disease fell short of statistical significance on the main goal of slowing disease progression in a four-year analysis, sending its U.S.-listed shares plummeting 55% in premarket trading on Tuesday.In the study with 12 high-dose patients, A…
UniQure NASDAQ:QURE, NASDAQ:QURE said on Tuesday its Huntington's treatment showed 44% slowing of disease progression, but did not reach statistical significance in an ongoing early-to-mid-stage trial.U.S.-listed shares of the Dutch gene therapy developer fell 63% in premarket trading.